FOLD · As filed with the SEC

Amicus Therapeutics cash flow statement, by quarter

The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024^† 3 months ended Sep 30, 2024	Q2 2024^† 3 months ended Jun 30, 2024	Q1 2024 3 months ended Mar 31, 2024
Operating activities
Net loss	1,690^†	17,306^†	(24,420)^†	(21,686)	14,739^†	(6,729)^†	(15,697)^†	(48,419)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing	676^†	658^†	630^†	606	597^†	574^†	560^†	531
Depreciation and amortization	1,897^†	1,874^†	1,852^†	1,837	2,041^†	2,170^†	2,182^†	2,154
Stock-based compensation	26,590^†	18,089^†	17,559^†	25,172	19,217^†	18,688^†	16,197^†	30,803
Non-cash changes in the fair value of contingent consideration payable	—	—	—	—	0^†	0^†	0^†	0
Foreign currency remeasurement loss	(3,622)^†	8,453^†	4,111^†	(5,356)	1,067^†	5,776^†	7,655^†	1,736
Other	—	(835)^†	2,794^†	1,175	—	528^†	702^†	5,818
Non-cash deferred taxes	—	—	—	—	0^†	0^†	0^†	0
Changes in operating assets and liabilities:
Accounts receivable	(614)^†	(8,084)^†	(12,492)^†	15,330	(10,394)^†	(8,643)^†	(10,004)^†	9,557
Inventories	(44,296)^†	(36,322)^†	(22,577)^†	(8,288)	(12,020)^†	(34,731)^†	(25,223)^†	(1,678)
Prepaid expenses and other current assets	(595)^†	7,570^†	(4,754)^†	(3,603)	(14,255)^†	14,257^†	19,299^†	(5,340)
Accounts payable, accrued expenses, and other current liabilities	38,143^†	30,627^†	10,360^†	3,647	(5,037)^†	(14,124)^†	27,124^†	(24,483)
Other non-current assets and liabilities	656^†	(3,676)^†	411^†	(1,076)	(2,033)^†	(737)^†	(104)^†	(374)
Payment of contingent consideration	—	—	—	—	0^†	0^†	—	—
Net cash provided by (used in) operating activities	16,253^†	35,660^†	(26,526)^†	7,758	(3,916)^†	(22,971)^†	22,691^†	(29,695)
Investing activities
Sale and redemption of marketable securities	16,857^†	17,256^†	10,995^†	6,161	15,904^†	39,540^†	23,428^†	38,907
Purchases of marketable securities	(23,052)^†	(18,173)^†	(14,370)^†	(38,810)	(36,008)^†	(4,912)^†	(44,307)^†	(29,559)
Capital expenditures	(299)^†	(382)^†	(2,403)^†	(212)	(288)^†	(356)^†	(1,098)^†	(1,811)
Net cash (used in) provided by investing activities	(6,494)^†	(1,299)^†	(5,778)^†	(32,861)	(20,392)^†	34,272^†	(21,977)^†	7,537
Financing activities
Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs	—	—	—	—	413^†	19,153^†	0^†	0
Withholding taxes paid on vested restricted stock units	(4,460)^†	(1,641)^†	(432)^†	(11,790)	(828)^†	(2,792)^†	(1,684)^†	(16,721)
Proceeds from stock options exercised, net	18,721^†	339^†	40^†	105	1,555^†	1,805^†	863^†	3,454
Proceeds from warrants exercised, net	—	—	—	—	0^†	0^†	—	—
Payment of contingent consideration	—	—	—	—	0^†	0^†	—	—
Payment of finance leases	(232)^†	(17)^†	(8)^†	(15)	(43)^†	24^†	(36)^†	(42)
Net cash provided by financing activities	14,029^†	(1,319)^†	(400)^†	(11,700)	1,097^†	18,190^†	(857)^†	(13,309)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(329)^†	(1,200)^†	9,987^†	4,819	3,107^†	(5,028)^†	(294)^†	(1,816)
Net increase (decrease) in cash, cash equivalents, and restricted cash	23,459^†	31,842^†	(22,717)^†	(31,984)	(20,104)^†	24,463^†	(437)^†	(37,283)
Cash, cash equivalents, and restricted cash at the beginning of the year	193,857	162,015	184,732	216,716	236,820	212,357	212,794	250,077
Cash, cash equivalents, and restricted cash at the end of the year	217,316	193,857	162,015	184,732	216,716	236,820	212,357	212,794
Supplemental disclosures of cash flow information
Tenant improvements paid through lease incentive	98^†	97^†	98^†	97	98^†	97^†	68^†	52
Cash paid during the period for interest	10,756^†	11,058^†	10,942^†	10,852	11,373^†	23,797^†	11,989^†	11,801
Cashless exercise of warrants	0^†	0^†	0^†	71	0^†	0^†	0^†	—
Capital expenditures unpaid at the end of period	73^†	(174)^†	36^†	138	(65)^†	78^†	(1,020)^†	1,110
Cash paid for income taxes	12,549^†	1,614^†	354^†	377	5,485^†	1,603^†	491^†	635

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.

Data on this page was fetched Nov 7, 2026, 5:20 PM ET. The filing on SEC.gov is the record.